Merck & Co., Inc. $MRK Shares Sold by Brown Shipley& Co Ltd

Brown Shipley& Co Ltd decreased its position in Merck & Co., Inc. (NYSE:MRK) by 20.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,398 shares of the company’s stock after selling 7,331 shares during the quarter. Merck & Co., Inc. accounts for approximately 2.1% of Brown Shipley& Co Ltd’s holdings, making the stock its 15th largest holding. Brown Shipley& Co Ltd’s holdings in Merck & Co., Inc. were worth $4,272,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Round Rock Advisors LLC lifted its position in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after buying an additional 66 shares in the last quarter. Cascade Financial Partners LLC raised its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares in the last quarter. Somerset Trust Co grew its stake in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares in the last quarter. Stonebridge Financial Group LLC lifted its stake in Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. lifted its stake in Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after acquiring an additional 82 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on MRK. Argus lifted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Morgan Stanley lowered their target price on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday. BMO Capital Markets raised their target price on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Finally, Wells Fargo & Company upped their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $151.32.

Insider Activity

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with PD-1/PD-L1 therapy. The decision expands Merck’s commercial oncology portfolio and could provide an additional growth opportunity alongside Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, adding a potentially valuable pipeline program. Merck Wins FDA Approval for WELIREG Plus LENVIMA
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while maintaining a neutral rating. The higher target reflects improved valuation support, although it implies limited upside at recent trading levels. Cantor Fitzgerald Raises Pharma Price Targets
• Neutral Sentiment: Analyst views remain divided: Morgan Stanley issued a buy rating in one report, while a separate report highlighted a pessimistic forecast. The conflicting outlooks suggest that Merck’s current valuation and future growth profile remain debated. Morgan Stanley Gives Merck a Buy Rating
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, but the relatively small holding is unlikely to materially affect the company’s fundamentals. Apella Capital Increases Merck Stake
• Negative Sentiment: A Dutch court blocked Merck’s subcutaneous Keytruda from being sold in eight European markets after Halozyme won an injunction in a patent dispute. The ruling could delay or restrict a potentially important, more convenient Keytruda formulation and increase litigation risk. Halozyme Wins Court Order Blocking Keytruda SC in Europe
• Negative Sentiment: Industry analysts identify Merck as one of the pharmaceutical companies most exposed to near-term generic competition as major patents expire. That patent-cliff risk could pressure revenue and earnings growth beyond the current period. Pharma Patent Cliff Risks

Merck & Co., Inc. Trading Up 2.4%

Shares of NYSE:MRK traded up $3.43 during midday trading on Friday, reaching $145.81. The company’s stock had a trading volume of 3,216,070 shares, compared to its average volume of 10,622,946. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm has a 50 day moving average price of $143.59 and a two-hundred day moving average price of $128.16. The firm has a market capitalization of $359.75 billion, a price-to-earnings ratio of 116.63, a PEG ratio of 6.42 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.